To address this common concern for patients, doctors, channel partners, manufacturers and regulators, Organisation of Pharmaceutical Producers of India (OPPI) in collaboration with drug manufacturers, the Indian Medical Association (IMA), AIOCD (pharmaceutical traders retailers and stockists) and other industry associations organised a seminar on anti-counterfeiting as part of the ‘Counterfeit Challenge’ initiative last week in Mumbai, first among the others held in Jaipur and Patna.

The event was facilitated by Mumbai based Business Management Advisory Services firm, SynCore Consulting.

The main agenda of the seminar was to discuss the implications of drug counterfeiting in India and to find out various measures currently being taken through active collaboration between various supply chain stakeholders like drug manufacturers, packaging companies, industry associations, regulatory bodies, logistics services providers and retailers to make India, a counterfeit-free market and hence, enhance the patient value.

The seminar was marked by the presence of eminent speakers from different segments of the pharmaceutical industry. Senior representatives from OPPI, AIOCD-AWACS, IMA; management consulting firms; directors of policy and government affairs; quality and security heads of leading pharmaceutical companies enlightened the participants with their thoughts on ways to tackle the challenge of counterfeiting.